The present disclosure is directed to a monoclonal antibody specific to B cell maturation antigen (BCMA) conjugated to a cytotoxin, or an antibody drug conjugate (ADC) comprising its antigen binding fragment.The present disclosure also provides a method for killing multiple myeloma cells by ...
目前针对BCMA靶向肿瘤免疫治疗MM研发主要围绕嵌合抗原受体T细胞(CAR-T,chimeric antigen receptor T-cell )、双特异性T细胞结合抗体(BiTE,Bispecific T-cell engager)和抗体偶联药物(ADC,Antibody Drug Conjugate )的疗法[4]。 CAR-T 图3:BCMA-CAR-T治疗[4] 通过对患者T细胞在体外进行工程化处理,CAR-T细胞上的抗...
[21] Lee L, Bounds D, Paterson J,et al. Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma [J]. British Journal of Haematology, 2016. [22] De-Xiu B, Reshma S, Choi E E,et al. Pre-clinical validation of B cell ...
1、GSK’s investigational BCMA antibody-drug conjugate receives Breakthrough Therapy Designation from US FDA for relapsed and refractory multiple myeloma 2、Targeting B-cell maturation antigen in multiple myeloma
参考资料:GSK announces further positive data from DREAMM-1 study of anti-BCMA antibody-drug conjugate in patients with relapsed/refractory multiple myeloma. Retrieved March 21, 2019, from https://www.gsk.com/en-gb/media/press-releases/gsk-announces-further-positive-data-from-dreamm-1-study-of...
据统计,截止至2024年1月,已公布的BCMA靶点药物大约有190+,包括如嵌合抗原受体(chimeric antigen receptor,CAR)-T细胞、双特异性抗体(bispecific antibodies,BsAbs)和抗体药物偶联物(antibody-drug conjugate,ADC)等免疫疗法。>>>点击了解高品质BCMA蛋白产品,支持动物免疫、抗体筛选、流式质控等应用。
Antibody-drug conjugate ADCC: Antibody-dependent cell-mediated cytotoxicity APRIL: A proliferation-inducing ligand ASCT: Autologous or allogenic stem cell transplantation BAFF: B cell activating factor BCMA: B cell maturation antigen BiTE: Bispecific T cell engager ...
[21] Lee L, Bounds D, Paterson J,et al. Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma [J]. British Journal of Haematology, 2016. [22] De-Xiu B, Reshma S, Choi E E,et al. Pre-clinical validation of B cell ...
BCMA antibody-drug conjugate (ADC) BCMA-targeted CAR-T cells BCMA CAR-T cells with tEGFR Bispecific CAR-T cells CAR-NK cells targeting BCMA Bispecific T cell engager (BiTE) and trispecific T cell engager (TiTE) BCMA-targeted therapeutics and future perspectives Conclusion Availability of data...
Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myelomadoi:10.1038/s41375-020-0834-9Hans C. LeeNoopur S. RajeOla LandgrenVijay V. UpretiJin WangAriel A. AvilionXuguang HuErik Rasmussen...